Omnicell (FRA:OC9) DeferredTaxAndRevenue: €247 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC9 Omnicell Inc FRA:OC9
76 GF Score
Price €39.80
GF Value €33.66
! 7 Warning Signs
View Full Analysis

What is Omnicell DeferredTaxAndRevenue?

Omnicell FRA:OC9 -1.00% 76 DeferredTaxAndRevenue is €247 Mil as of Mar. 2026. GuruFocus rates FRA:OC9 with a GF Score™ of 76/100 and a GF Value™ of €33.66. The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Omnicell's current deferred tax and revenue for the quarter that ended in Mar. 2026 was €247 Mil.

Omnicell DeferredTaxAndRevenue Related Terms

Omnicell DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Omnicell's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omnicell DeferredTaxAndRevenue Chart

Omnicell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.62 176.72 161.33 192.89 242.09

Omnicell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.18 183.12 210.52 242.09 247.38
FRA:OC9
76GF Score
Omnicell Inc FRA:OC9
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €247 Mil mean?
Omnicell (FRA:OC9) has a DeferredTaxAndRevenue of €247 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Omnicell.
Is Omnicell's DeferredTaxAndRevenue too high?
Omnicell's current DeferredTaxAndRevenue is €247 Mil. Overall, Omnicell has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's DeferredTaxAndRevenue compare to TDOC and SDGR?
Omnicell's DeferredTaxAndRevenue of €247 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Healthcare Providers & Services company?
A good DeferredTaxAndRevenue depends on the Healthcare Providers & Services industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Omnicell. Omnicell's current DeferredTaxAndRevenue is €247 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (FRA:OC9) has a current DeferredTaxAndRevenue of €247 Mil. The stock's GF Value™ is €33.66, compared to a current price of €39.80 — trading 18.2% above its estimated fair value. The current DeferredTaxAndRevenue is €247 Mil. Omnicell's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Omnicell (FRA:OC9), the current DeferredTaxAndRevenue is €247 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Omnicell (FRA:OC9) Overvalued in 2026?

Based on GuruFocus' analysis, Omnicell stock appears to be overvalued. The current stock price of €39.80 is trading 18.2% above its estimated GF Value™ of €33.66.

Key valuation signals for FRA:OC9:

  • DeferredTaxAndRevenue: €247 Mil
  • GF Value™: €33.66 vs. price of €39.80 (18.2% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Omnicell Business Description

Other Exchanges OMCL:USAOMCL:Mexico
Address 4220 North Freeway, Fort Worth, TX, USA, 76137
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
76GF Score

Get the complete analysis for FRA:OC9

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.80
Price
€33.66
GF Value